CrossAssetDataThe Company File
···
VCYT

Veracyte, Inc.

Veracyte, Inc. is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in South San Francisco, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $517 million and a profit of $66 million (its filed statements).

Usage business Services-Medical Laboratories South San Francisco, CA filings since 2006 9 of 9 filed
Ask the desk about VCYT → Compare VCYT with FLGT → Price chart on TradingView ↗ Full EDGAR file ↗ Watch VCYT →

Sector peers: FLGTCAIGHNTRA

6.3/10headline grade
vs its business-model standard
6.0/10past 6.7/10present 6.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.3 out of ten, 9 of 9 metrics filed: past 6.0 out of ten, present 6.7 out of ten, future 6.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2017. 78th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.5 out of ten. +25.9% a year over 10 filed years; profitable in 2 of 8. 55th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 4.6 out of ten. Share count grew 4.0% a year. 0% of cash flow returned. Insiders: 61 sales, 0 purchases. 46th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 7.3 out of ten. ROE 5%: 5¢ of profit per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar. 73rd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.4 out of ten. top 26% of 23 in its family; net margin 12.8%. 74th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.1 out of ten. bottom 41% of 17 in its family for leadership; chief executive since 2021. 41st percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 6.8 out of ten. top 32% of 23 in its family for room to expand. 68th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.5 out of ten. top 45% of 23 in its family for growth drivers. 55th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.4 out of ten. top 36% of 20 in its family for expectations against reality. 64th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-31 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 (on EDGAR). Newest filing: Form 144, 2026-09-24. Filings on record since 2006. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Testing 95%, Biopharmaceutical and Other 2%, Biopharmaceutical and Other Biopharmaceutical Revenue 1%, Testing Other 1%, Biopharmaceutical and Other Contract Manufacturing and Testing 1%. By geography: United States 96%, International 4%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Stapley, Marc (Chief Executive Officer); Chambers, Rebecca (Chief Financial Officer); Leite, John (Global Chief Commercial Off); Febbo, Phillip G. (Chief Scientific & Med Officer); Wygant, Jonathan (VP, Chief Accounting Officer); Haas, Kevin Richard (Chief Dev and Tech Officer); Mcguire, Annie (EVP, General Counsel); Holstein, Jens (director); Bhanji, Muna (director); Eastham, Karin (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.